Ken Griffin Pliant Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$10.52 - $14.35 $162,008 - $220,990	-15,400 Reduced 45.03%	18,800 $210,000
Q2 2024 Aug 14, 2024	BUY	$10.58 - $15.61 $81,466 - $120,197	7,700 Added 29.06%	34,200 $367,000
Q1 2024 May 15, 2024	BUY	$14.14 - $19.59 $100,394 - $139,089	7,100 Added 36.6%	26,500 $394,000
Q4 2023 Feb 14, 2024	SELL	$12.85 - $19.15 $373,935 - $557,265	-29,100 Reduced 60.0%	19,400 $351,000
Q3 2023 Nov 14, 2023	BUY	$14.58 - $20.15 $71,442 - $98,735	4,900 Added 11.24%	48,500 $840,000
Q2 2023 Aug 14, 2023	SELL	$18.12 - $30.56 $157,644 - $265,872	-8,700 Reduced 16.63%	43,600 $790,000
Q1 2023 May 15, 2023	BUY	$18.73 - $36.26 $288,442 - $558,404	15,400 Added 41.73%	52,300 $1.39 Million
Q4 2022 Feb 14, 2023	SELL	$17.0 - $25.43 $532,100 - $795,959	-31,300 Reduced 45.89%	36,900 $713,000
Q3 2022 Nov 14, 2022	BUY	$7.67 - $24.23 $367,393 - $1.16 Million	47,900 Added 235.96%	68,200 $1.43 Million

168

63.2M

245K

373K

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $649M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.